Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07711-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Chunhui Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Translational Research, Biomedical, Gelatinases, Membrane Proteins, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) has emerged as a novel strategy for modulating the tumour microenvironment (TME) by selectively eradicating FAP-expressing cancer-associated fibroblasts (CAFs). Although preclinical studies have demonstrated promising results across various tumour models using diverse radiolabelled FAP inhibitors, clinical translation remains limited by modest efficacy, short tumour retention, and highly heterogeneous responses. This review aims to provide an overview of recent advances in radiopharmaceutical design to enhance tumour targeting and prolong retention. Furthermore, we summarise early clinical findings and ongoing trials, while emphasising the potential translational challenges of FAP-TRT. Special emphasis is placed on the radiobiological underpinnings of FAP-TRT, including the impact of CAFs heterogeneity, potential pro-tumorigenic effects of sublethal irradiation, and the uncertain contribution of bystander and abscopal effects. We further highlight the need for the development of translationally relevant tumour models, optimised dosimetry, predictive biomarkers, and refined patient selection criteria. Finally, we propose future directions such as combination therapy with immune checkpoint inhibitors (ICIs). Together, these insights aim to bridge the gap between promising preclinical efficacy and limited clinical outcomes in FAP-TRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. b.t.cornelissen@umcg.nl.
ORCID-Profile: Bart Cornelissen
Zitieren
APA
Wu, C., Kurniawan, A., Ming, Z., Antunes, I. F., Noordzij, W., Glaudemans, A., & Cornelissen, B. (2026). Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07711-3
Vancouver
Wu C, Kurniawan A, Ming Z, Antunes IF, Noordzij W, Glaudemans A, et al. Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07711-3
BibTeX
@article{Wu2026,
author = {Wu, Chunhui and Kurniawan, Ahmad and Ming, Zihe and Antunes, Ines F and Noordzij, Walter and Glaudemans, Andor and Cornelissen, Bart},
title = {Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07711-3}
}
EUVIMED